PPARA and metabolic dysfunction-associated steatohepatitis: In a study of NASH patients, it was found that treating with GS-0976 20 mg per day for 12 weeks reduced liver steatosis, selective markers of liver fibrosis, and biochemistry but caused significant increases in serum TG levels in most patients (64); this asymptomatic hypertriglyceridemia can be partially resolved by fibrate (belonging to PPARα agonists).